CONTACT US
Home > Inhibitors/Agonists> > Motexafin gadolinium
Motexafin gadolinium

Motexafin gadolinium

  • CAT Number: I007581
  • CAS Number: 246252-06-2
  • Molecular Formula: C52H72GdN5O14
  • Molecular Weight: 1148.419
  • Purity: ≥95%
Inquiry Now

Motexafin gadolinium, also known as PCI 0120, is a synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially due to their increased rates of metabolism, generating reactive oxygen species (ROS) intracellularly and lowering the tumor cell apoptotic threshold to ionizing radiation and chemotherapy.

Catalog Number I007581
CAS Number 246252-06-2
Synonyms

PCI 0120; PCI-0120; PCI0120; API-GP 3; Gd texaphyrin; Gd-Texgadolinium; texaphyrin; Gd (III) Texaphryin. US brand name: Xcytrin. Abbreviation: GdTex.;Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dim

Molecular Formula

C52H72GdN5O14

Purity 95%
Solubility Soluble in DMSO, not in water
Storage 0 - 4°C for short term , or -20°C for long term.
InChI InChI=1S/C48H66N5O10.2C2H4O2.Gd/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;2*1-2(3)4;/h27-32,54-55H,7-
InChIKey LAUAZTXAMPOVHP-WRIGXHCHSA-L, VAZLWPAHMORDGR-WRIGXHCHSA-L
SMILES CCC1=C(N2[Gd-4]3456(OC(C)=O)OC(C)=O)C=C7[N+]4=C(C=[N+]6C8=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C8[N+]5=CC(C(C)=C9CCCO)=[N+]3C9=CC2=C1CC)C(C)=C7CCCO
Reference

</br>1:Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator. Thiabaud G, McCall R, He G, Arambula JF, Siddik ZH, Sessler JL.Angew Chem Int Ed Engl. 2016 Oct 4;55(41):12626-31. doi: 10.1002/anie.201604236. Epub 2016 Jul 5. PMID: 27377046 </br>2:Gliomas: Motexafin Gadolinium-enhanced Molecular MR Imaging and Optical Imaging for Potential Intraoperative Delineation of Tumor Margins. Qiu L, Zhang F, Shi Y, Bai Z, Wang J, Li Y, Lee D, Ingraham C, Feng X, Yang X.Radiology. 2016 May;279(2):400-9. doi: 10.1148/radiol.2015150895. Epub 2015 Nov 24. PMID: 26599802 Free PMC Article</br>3:Phase 1/2 trials of Temozolomide, Motexafin Gadolinium, and 60-Gy fractionated radiation for newly diagnosed supratentorial glioblastoma multiforme: final results of RTOG 0513. Brachman DG, Pugh SL, Ashby LS, Thomas TA, Dunbar EM, Narayan S, Robins HI, Bovi JA, Rockhill JK, Won M, Curran WP.Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):961-7. doi: 10.1016/j.ijrobp.2014.12.050. PMID: 25832688 Free PMC Article</br>4:3.0-T MR imaging of intracoronary local delivery of motexafin gadolinium into coronary artery walls. Meng Y, Wang J, Sun J, Zhang F, Willis P, Li J, Wang H, Zhang T, Soriano S, Qiu B, Yang X.Radiology. 2013 Aug;268(2):556-62. doi: 10.1148/radiol.13121451. Epub 2013 Mar 19. PMID: 23513243 Free PMC Article</br>5:MRI-monitored intra-shunt local agent delivery of motexafin gadolinium: towards improving long-term patency of TIPS. Wang H, Zhang F, Meng Y, Zhang T, Willis P, Le T, Soriano S, Ray E, Valji K, Zhang G, Yang X.PLoS One. 2013;8(2):e57419. doi: 10.1371/journal.pone.0057419. Epub 2013 Feb 28. PMID: 23468986 Free PMC Article</br>6:Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children/’s oncology group phase 2 study. Bradley KA, Zhou T, McNall-Knapp RY, Jakacki RI, Levy AS, Vezina G, Pollack IF.Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):e55-60. doi: 10.1016/j.ijrobp.2012.09.004. Epub 2012 Oct 22. PMID: 23092726 Free PMC Article</br>7:Safety and feasibility of motexafin gadolinium administration with whole brain radiation therapy and stereotactic radiosurgery boost in the treatment of ≤ 6 brain metastases: a multi-institutional phase II trial. McHaffie DR, Chabot P, Dagnault A, Suh JH, Fortin MA, Chang E, Timmerman R, Souhami L, Grecula J, Nabid A, Schultz C, Werner-Wasik M, Gaspar LE, Brachman D, Mody T, Mehta MP.J Neurooncol. 2011 Nov;105(2):301-8. doi: 10.1007/s11060-011-0590-9. Epub 2011 Apr 27. PMID: 21523486 </br>8:Ascorbate and endocytosed Motexafin gadolinium induce lysosomal rupture. Berndt C, Kurz T, Bannenberg S, Jacob R, Holmgren A, Brunk UT.Cancer Lett. 2011 Aug 28;307(2):119-23. doi: 10.1016/j.canlet.2011.03.023. Epub 2011 Apr 13. PMID: 21492999 </br>9:Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R.J Thorac Oncol. 2011 Apr;6(4):786-9. doi: 10.1097/JTO.0b013e31820a443f. PMID: 21289521 Free Article</br>10:Motexafin gadolinium: a promising radiation sensitizer in brain metastasis. Thomas SR, Khuntia D.Expert Opin Drug Discov. 2011 Feb;6(2):195-203. doi: 10.1517/17460441.2011.546395. PMID: 22647136

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!